Clinical Trial

A Clinical Trial of TQB6426 for Injection in Patients With Advanced Solid Tumors

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
TQB6426 is a glypican-3 (GPC3)-targeted antibody-drug conjugate (ADC) independently developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Preclinical studies have demonstrated its potent anti-tumor activity coupled with a favorable therapeutic safety window, which provides sufficient pharmacological and toxicological evidence to support the initiation of human clinical trials.
Protocol Amendment History 1 change
notable Trial sites expanded: 1 -> 8 locations 2026-08-07
Trial Details
NCT Number NCT07730190
Lead Sponsor Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Conditions Advanced Malignancies
Enrollment 151 participants
Start Date 2026-08
Primary Completion 2027-08 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2026-08-06